GLP-1 (7-37) | CAS 106612-94-6 | Incretin Hormone Fragment (Research Use Only) | Knowlux

Product Description

GLP-1 (7-37), CAS 106612-94-6, is a synthetic glucagon-like peptide-1 fragment supplied by Knowlux for laboratory research use. It corresponds to the biologically active N-terminal fragment of proglucagon (residues 78-108) and comprises 31 amino acid residues with a free C-terminal glycine. The molecular formula is C151H228N40O47 and the molecular weight is 3355.67 g/mol. Each lot is released with a lot-specific COA, MSDS and full analytical traceability.

Product Parameters

Product Details

1. Overview

GLP-1 (7-37) is the truncated, biologically active form of glucagon-like peptide-1, produced by post-translational processing of proglucagon in intestinal L-cells. The (7-37) designation refers to the sequence spanning residues 7 through 37 of the parent GLP-1 molecule, which retains full receptor agonist activity while the (7-36) amide is the other major circulating form. Native GLP-1 has an extremely short plasma half-life of 1.5-2 minutes due to rapid cleavage by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidases. In research settings, GLP-1 (7-37) is used as the reference agonist for GLP-1 receptor binding and functional studies, and serves as the molecular template from which longer-acting analogues (liraglutide, semaglutide, tirzepatide) have been engineered.

2. Mechanism of Action

GLP-1 (7-37) binds the GLP-1 receptor (GLP-1R), a class B G protein-coupled receptor expressed on pancreatic beta cells, as well as in the brain, heart, and gastrointestinal tract. Receptor activation is Gs-coupled, leading to adenylyl cyclase activation and cAMP accumulation. In beta cells, this cascade potentiates glucose-dependent insulin secretion through PKA- and Epac2-mediated pathways. The N-terminal histidine residue is essential for receptor activation; even minor modifications at this position can abolish agonist activity. Beyond insulinotropic effects, GLP-1R agonism slows gastric emptying, suppresses glucagon release during hyperglycaemia, and reduces food intake through hypothalamic signalling. In published rat studies, GLP-1 (7-37) infusion produced dose-dependent increases in glucose-stimulated plasma insulin and glucose infusion rates during hyperglycaemic clamp.

3. Quality Control

Full COA, MSDS, and lot-specific chromatograms are issued with each shipment. Custom specifications and third-party inspection can be arranged.

4. Applications

• Reference standard and impurity studies for GLP-1 receptor agonist analytical methods

• GLP-1R binding and functional assay development

• In vitro insulin secretion and beta-cell function studies

• Formulation development for GLP-1-based injectable peptides

• LC-MS, immunoassay and bioassay calibrators

5. Packaging, Storage & Shipping

Lyophilized powder: amber glass vial under nitrogen headspace, sealed with butyl stopper and aluminium crimp. Secondary packing: tamper-evident, light-protected carton with desiccant. Cold-chain shipping with validated gel packs and temperature logger; dry ice for -20 C or -80 C shipments. COA, MSDS, packing list and certificate of origin issued with each shipment.

6. Documentation Support

Per lot: COA, MSDS, certificate of origin, residual solvent statement, counter-ion specification. Regulatory packages (specification summaries, audit support) available on a project basis.

About Knowlux

Knowlux Biotechnology is a GMP-oriented manufacturer and supplier of peptides, APIs and fine-chemical research compounds, operating from Hubei, China. We serve research groups, CDMOs and distributors in more than 40 countries, and support contract synthesis, custom packaging and technical documentation requests.

Compliance Statement

This product is supplied for laboratory research use only. It is not for human or animal administration, not for diagnostic or therapeutic use, not for retail sale, and not for personal use. GLP-1 (7-37) is an endogenous peptide fragment and is not approved as a therapeutic product in any jurisdiction. Research context statements are for scientific reference only and do not constitute medical advice, promotional claims, or dosing guidance.